Related Experiment Videos
Identification of novel survivin-derived CTL epitopes
Sine Reker1, Anders Meier, Lars Holten-Andersen
1Tumor Immunology Group, Division of Canter Biology, Danish Cancer Society, Copenhagen, Denmark.
Cancer Biology & Therapy
|January 17, 2004
Summary
Scientists identified new survivin epitopes for cancer immunotherapy. These targets, recognized by cytotoxic lymphocytes (CTLs), expand patient eligibility for survivin peptide-based treatments and reduce immune escape risks.
Area of Science:
- Immunology
- Oncology
- Cancer Immunotherapy
Background:
- Tumor antigens are crucial for cancer cell survival and represent therapeutic targets.
- Immunoselection can lead to antigen loss variants, particularly during immunotherapy.
- Survivin is an inhibitor of apoptosis protein and a potential tumor antigen.
Purpose of the Study:
- To identify novel survivin-derived epitopes restricted by various HLA alleles (HLA-A1, HLA-A2, HLA-A3, HLA-A11).
- To characterize spontaneous cytotoxic lymphocyte (CTL) responses against these novel epitopes in cancer patients.
- To expand patient eligibility for survivin-based peptide immunotherapy and mitigate immune escape.
Main Methods:
- Characterization of novel HLA-restricted survivin epitopes.
- Analysis of spontaneous CTL responses in cancer patients.
- Assessment of epitope targeting across multiple HLA restriction elements.
Main Results:
- Identification and characterization of novel HLA-A1, HLA-A2, HLA-A3, and HLA-A11-restricted survivin epitopes.
- Demonstration of spontaneous CTL responses against these survivin epitopes in cancer patients.
- Increased patient eligibility for survivin peptide-based immunotherapy.
Conclusions:
- Novel survivin epitopes broaden the scope of survivin-based cancer immunotherapy.
- Targeting multiple HLA-restricted survivin epitopes enhances therapeutic potential.
- This strategy may reduce the risk of immune escape through HLA-allele loss.